Number of antihypertensive drugs at 1 year after kidney transplantation

Area of Science:

• Nephrology
• Transplantation Medicine
• Cardiovascular Medicine

Background:

• High blood pressure (hypertension) is prevalent in kidney transplant recipients (up to 90%).
• Hypertension negatively impacts patient and graft survival rates post-transplant.
• Kidney Disease/Improving Global Outcomes (KDIGO) guidelines recommend blood pressure below 130/80 mm Hg.

Purpose of the Study:

• To analyze the number of antihypertensive drugs used in kidney transplant recipients one year post-transplantation.
• To determine the influence of the number of antihypertensive drugs on patient and graft outcomes.
• To identify risk factors associated with requiring more antihypertensive medications.

Main Methods:

• Retrospective analysis of 411 deceased-donor kidney transplantation cases.
• Data collected from a prospectively maintained institutional database.
• Blood pressure measured in outpatient clinics; antihypertensive drug use categorized.

Main Results:

• The number of antihypertensive drugs was significantly associated with lower patient survival rates, independent of other factors.
• High body mass index, male recipient gender, donor hypertension, prior acute rejection, and cyclosporine therapy were linked to increased drug requirements.
• Approximately 97 patients required no therapy, while 130, 119, 52, and 13 needed 1, 2, 3, or 4 drugs, respectively.

Conclusions:

• The quantity of antihypertensive drugs is a measurable indicator of reduced patient survival post-kidney transplant.
• Modifiable factors such as recipient body mass index, calcineurin inhibitor type, and acute rejection control are key targets.
• Optimizing management of these factors may decrease the need for antihypertensive medications and improve long-term outcomes.